Terbinafine: An update

Journal of the American Academy of Dermatology

Volumn 37, Issue 6, 1997, Pages 979-988

  Gupta, A K ^a   Shear, N H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE;

DERMATOMYCOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; NEUROTOXICITY; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TASTE DISORDER; UNITED STATES; VISUAL IMPAIRMENT;

EID: 0031443914     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(97)70076-8     Document Type: Article

References (120)

1. D Berney K. Schuh 125, Heterocyclic spiro-naphthalenones. Part 1: synthesis and reactions of some spiro [(1 H-naphthalenome)]-1,3,-piperidines Helv Chir Acta 61 1978 1262 1273
2. NS. Ryder Terbinafine: mode of action and properties of the squalene epoxidase inhibition Br J Dermatol 126 Suppl 39 1992 2 7
3. G Petranyi JG Meingassner H. Mieth Antifungal activity of the allylamine derivative terbinafine in vitro Antimicrob Agents Chemother 31 1987 1365 1368
4. G Petranyi A Stütz NS Ryder J Meingassner H. Mieth Experimental antimycotic activity of naftifine and terbinafine RA Fromtling Recent trends in the discovery: development and evaluation of antifungal agents. 1987 JR Prous Science Publishers S.A Barcelona 441 450
5. JA Balfour D. Faulds Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses Drugs 43 1992 259 284
6. A Rashid EM Scott MD. Richardson Effects of terbinafine exposure on the ultrastructure of Trichophyton interdigitale J Med Vet Mycol 31 1993 305 313
7. A Stephen R Czok O. Male Terbinafine: initial clinical results RA Fromtling Recent trends in the discovery, development and evaluation of antifungal agents. 1987 JR Prous Science Publishers S.A Barcelona 511 520
8. JM Kovarik S Kirkesseli H Humbert P Grass K. Kutz Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers Br J Dermatol 126 Suppl 39 1992 8 13
9. H Zehender J Denouël J Faergemann P Donatsch K Kutz H. Humbert Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites Drug Invest 8 1994 203 210
10. JC. Jensen Pharmacokinetics of Lamisil in humans J Dermatol Treat 1 Suppl 2 1990 15 18
11. LR Lever PJ Dykes R Thomas AY. Finlay How orally administered terbinafine reaches the stratum corneum J Dermatol Treat 1 1990 23 25
12. J Faergemann H Zehender T Jones I. Maibach Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat Acta Derm Venereol (Stockh) 71 1990 322 326
13. J Faergemann H Zehender J Denouël L. Millerioux Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks Acta Derm Venereol (Stockh) 73 1993 305 309
14. J Faergemann H Zehender L. Millerioux Levels of terbinafine in plasma, stratum corueum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days Clin Exp Dermatol 19 1994 121 126
15. F Schatz M Bräutigam E Dobrowolski I Effendy H Haberl H Mensing Nail incorporation kinetics of terbinafine in onychomycosis patients Clin Exp Dermatol 20 1995 377 383
16. Terbinafine Product Monograph April 1996 Sandoz Pharmaceuticals East Hanover (NJ)
17. JC. Jensen Clinical pharmacokinetics of terbinafine (Lamisil) Clin Exp Dermatol 14 1989 110 113
18. P Esterre CK Inzan ER Ramarcel A Andriantsimahavandy M Ratsioharana JL Pecarrere Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study Br J Dermatol 134 Suppl 46 1996 33 36
19. TC. Jones Overview of the use of terbinafine (Lamisil) in children Br J Dermatol 132 1995 683 689
20. V Goulden MJD. Goodfield Treatment of childhood dermatophyte infections with oral terbinafine Pediatr Dermatol 12 1995 53 54
21. TS Haroon I Hussain A Mahmood Ah Nagi I Ahmad M. Zahid An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis Br J Dermatol 126 1992 47 50
22. F Nejjam M Zagula MD Cabiac N Guessous H Hubert H. Lakhdar Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics Br J Dermatol 132 1995 98 105
23. TS Haroon I Hussain S Aman M Jahangir AH Kazmi AR Sami A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis Br J Dermatol 135 1995 86 88
24. M Del Carmen Padilla Desgarennes MR Godoy AB. Palencia Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans J Am Acad Dermatol 35 1996 114 116
25. F Baudraz-Rosselet M Monod S Jaccoud E. Frenk Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species Br J Dermatol 135 1996 1011 1012
26. AD Burden DM Tillman MD. Richardson Human Trichophyton equinum infection treated with terbinafine Clin Exp Dermatol 19 1994 359 360
27. AK Gupta RG Sibbald CW Lynde PR Hull R Prussick NH Shear Onychomycosis in children: prevalence and treatment strategies J Am Acad Dermatol 36 1997 395 402
28. Terbinafine product monograph, Canada November 1995 Sandoz Canada Inc Dorval, Quebec 1 33
29. Terbinafine product monograph, United Kingdom October 1993 Sandoz Pharmaceuticals (UK) Ltd Frimley
30. Terbinafine product monograph, Australia February 1995 Sandoz Australia Pty Ltd, Pharmaceutical Division North Hyde
31. N Zaias L. Serrano The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine Clin Exp Dermatol 14 1989 120 123
32. MJD Goodfield NR Rowell RA Forster EGV Evans A. Raven Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent Br J Dermatol 121 1989 753 757
33. T. Rakosi Terbinafine and onychomycosis [abstract] Dermatologica 181 1990 174
34. MJD. Goodfield Clinical results with terbinafine in onychomycosis J Dermatol Treat 1 1990 55 57
35. DF. Eastcott Terbinafine and onychomycosis [letter] N Z Med J 104 1991 17
36. MJD. Goodfield Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial Br J Dermatol 126 1992 33 35
37. JG Van Der Schroeff PKS Cirkel MB Crijns TJA Van Dijk FJ Govaert DA Groeneweg A randomized treatment duration-finding study of terbinafine in onychomycosis Br J Dermatol 126 1992 36 39
38. F Baudraz-Rosselet T Rakosi PB Wili R. Kenzelmann Treatment of onychomycosis with terbinafine Br J Dermatol 126 1992 40 46
39. B Cribier E. Grosshans Efficacité et to1érance de la terbinafine (Lamisil) dans une série de 50 onychomycoses á dermatophytes Ann Dermatol Venereol 121 1994 15 20
40. E Haneke I Tausch M Bräutigam G Weidinger D Welzel LAGOS III Study Group Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin J Am Acad Dermatol 32 1995 72 77
41. J Faergemann C Anderson K Hersle E Hradil P Nordin T Kaaman Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis J Am Acad Dermatol 32 1995 750 753
42. R Galimberti A Kowalczuk V Flores L. Squiquera Onychomycosis treated with a short course of oral terbinafine Int J Dermatol 35 1996 374 375
43. H Hofmann M Bräutigam G Weidinger H. Zaun Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin Arch Dermatol 131 1995 919 922
44. R Arenas J Dominguez-Cherit LM. Fernández Open randomized comparison of itraconazole versus terbinafine in onychomycosis Int J Dermatol 34 1993 138 143
45. M Bräutigam S Nolting RE Schopf G. Weidinger Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection BMJ 311 1995 919 922
46. PJ Velthuis M. Nijenhuis Treatment of onychomycosis with terbinafine in patients with Down's syndrome Br J Dermatol 133 1995 144 145
47. A Watson J Marley D Ellis T. Williams Terbinafine in onychomycosis of the toenail: a novel treatment protocol J Am Acad Dermatol 33 1995 775 779
48. A Tosti BM Piraccini C Stinchi N Venturo F Bardazzi MD. Colombo Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy J Am Acad Dermatol 34 1996 595 600
49. M De Backer P De Keyser C De Vroey E. Lesaffre A 12- week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day—a double blind comparative trial Br J Dermatol 134 Suppl 46 1996 16 17
50. KH Lee YS Kim MS Kim HS Chung K. Park Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients Transplant Proc 28 1996 1488 1489
51. R DerSimonian N. Laird Meta-analysis in clinical trials Controlled Clin Trials 7 1986 177 188
52. V. Velanovich Meta-analysis for combining Bayesian probabilities Med Hypotheses 35 1991 192 195
53. R Nandwani A Pamell M Youle CJN Lacey EGV Evans J Midgley Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis Br J Dermatol 134 Suppl 46 1996 22 24
54. PK Buxton FJ. Prescott The response to Lamisil of dermatophyte infection in diabetic patients Eur Acad Dermatol Venereol 7 1996 293 294
55. S Shuster C. Munro Single dose treatment of fungal nail disease Lancet 339 1992 1066
56. CK Wong YL. Cho Very short duration therapy with oral terbinafine for fingernail onychomycosis Br J Dermatol 133 1995 329 347
57. E Alpsoy E Yilmaz E. Basaran Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach J Dermatol 23 1996 259 262
58. M De Backer P De Keyser DL Massart KJ Westelinck for the multicentre study group Terbinafine (Lamisil) 250 mg/day and 500 mg/day are equally effective in a 16-week oral treatment of toenail onychomycosis: a double blind multicenter trial RJ Hay International perspective on Lamisil; CCT Health Care Congress and Symposium Series vol 101 1994 CCT Healthcare Communications Ltd London 39 43
59. C. De Cuyper Long-term evaluation of terbinafine 250 and 500 mg daily in a 16 week oral treatment for toenail onychomycosis Br J Dermatol 135 1996 156 157
60. R Segal A Kritzman L Cividalli Z Samra M. David Treatment of Candida nail infection with terbinafine J Am Acad Dermatol 35 1996 958 961
61. EG Jung PJ Haas M Bräutigam G. Weidinger Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole Mycoses 37 1994 361 365
62. DT Roberts MD Richardson PK Dwyer R. Donegan Terbinafine in chronic paronychia and candida onychomycosis J Dermatol Treat 2 Suppl 1 1992 39 42
63. S Nolting M Bräutigam G. Weidinger Terbinafine in onychomycosis with involvement by non-dermatophyte fungi Br J Dermatol 130 Suppl 43 1994 16 21
64. A Tosti BM Piraccini C Stinchi S. Lorenzi Onychomycosis due to Scopulariopsis brevicaulis : clinical features and response to systemic antifungals Br J Dermatol 135 1996 799 802
65. RC. Savin Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis J Am Acad Dermatol 23 Suppl 1990 807 809
66. RJ Hay RA Logan MK Moore G Midgely YM. Clayton A comparative study of terbinafine versus griseofulvin in 'dry type' dermatophyte infections J Am Acad Dermatol 24 1991 243 246
67. RC. Savin Successful treatment of chronic tinea pedis (moccasin-type) with terbinafine (Lamisil®) Clin Exp Dermatol 14 1989 116 119
68. RC. Sayin Terbinafine (Lamisil®) versus griseofulvin in moccasin type tinea pedis J Dermatol Treat 1 Suppl 2 1990 43 46
69. JE White PJ Perkins EGV. Evans Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum Br J Dermatol 125 1991 260 262
70. P De Keyser M De Backer DL Massart KJ. Westelinck Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study Br J Dermato1 130 1994 22 25
71. RFE. De Wit A randomized double-blind multicentre comparative study of Lamisil (terbinafine) versus ketoconazole in tinea corporis J Dermatol Treat 1 1990 41 42
72. GW Cole G. Sticklin A comparison of a new oral antifungal, terbinafine, with griseofulvin as therapy for tinea corporis Arch Dermatol 125 1989 1537 1539
73. A Del Palacio Hernanz SL Gómez FG. Lastra A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris Clin Exp Dermatol 15 1990 210 216
74. A Farag M Taha S. Halim One-week therapy with oral terbinafine in cases of tinea cruris/corporis Br J Dermatol 131 1994 648 686
75. U Budimulja K Kuswadji S Bramono J Basuki LS Judanarso S Untung A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole Br J Dermatol 130 1994 29 31
76. AK Gupta R Prussick RG Sibbald SR. Knowles Terbinafine in the treatment of Majocchi's granuloma Int J Dermatol 34 1995 489
77. PR Hull HF. Vismer Treatment of cutaneous sporotrichosis with terbinafine Br J Dermatol 126 1992 51 55
78. L. Gip Black piedra: the first case treated with terbinafine (Lamisil) Br J Dermatol 130 1994 26 28
79. M Hall C Monka P Krupp D. O'Sullivan Safety of oral terbinafine: results of a postmarketing surveillance study in 25 884 patients Arch Dermatol 133 1997 1213 1219
80. DP O'Sullivan CA Needham A Bangs K Atkin FD. Kendall Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study Br J Clin Pharmacol 41 1996 1 7
81. BHC Stricker MM Van Riemsdijk MCJM Sturkenboom JP. Ottervanger Taste loss to terbinafine: a case-control study of potential risk factors [abstract] Pharmacoepidemiol Drug Safety 4 1995 522
82. KU Schentke H Porst L. Tschopel Drug-induced liver damage from the clinical viewpoint Gastroenterology 50 1990 12 15
83. H. Breithaupt Drug-induced liver damage caused by antirheumatic drugs: antirheumatic therapy in pre-existing liver damage Z Rheumatol 53 1994 250 254
84. C. Benichou Adverse drug reaction: a practical guide to diagnosis and management 1994 John Wiley & Sons New York 3 9
85. SC Montamat BJ Cusack RE. Vestal Management of drug therapy in the elderly N Engl J Med 321 1989 303 309
86. GC Farrell Drug-induced liver disease. 1994 Churchill Livingstone New York 85 89
87. G Lowe C Green P. Jennings Hepatitis associated with terbinafine treatment [letter] Br Med J 306 1993 248
88. J van't Wout WA Herrmann RA de Vries BH. Strickes Terbinafine-associated hepatic injury J Hepatol 21 1994 115 117
89. OY Boldewijn JP Ottervanger CMJA Mostart AR Janssens JCEGJPM Jonkers Hepatitis toegeschreven aan het gebruik van terbinafine Ned Tijdschr Geneeskd 23 1996 669 672
90. Hepatobiliary reactions with terbinafine hydrochloride Can Med Assoc J 154 1996 62 63
91. AK Gupta J Kopstein NH. Shear Hypersensitivity reaction to terbinafine J Am Acad Dermatol 36 1997 1018 1019
92. Adverse reactions to drugs 1996 WHO Collaborating Centre for Intemational Drug Monitoring Uppsala, Sweden
93. P Todd S Halpern DD. Munro Oral terbinafine and erythema multiforme Clin Exp Dermatol 20 1995 247 248
94. SI White D. Bowen-Jones Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics Br J Dermatol 134 1996 188 189
95. JM McGregor MHA. Rustin Terbinafine and erythema multiforme Br J Dermatol 131 1994 587 588
96. B Rzany M Mockenhaupt W Gehring E. Schöpf Stevens-Johnson syndrome after terbinafine therapy [letter] J Am Acad Dermatol 30 1994 509
97. J Carstens P Wendelboe H Sogaard K. Thestrup-Pedersen Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine Acta Derm Venereol (Stockh) 74 1994 391 392
98. SE Munn R. Russell Jones Terbinafine and fixed drug eruption Br J Dermatol 133 1995 815 816
99. N Dupin I Gorin V Djien H Helal L Zylbberberg M Leibowitch Acute generalized exanthematous pustulosis induced by terbinafine Arch Dermatol 132 1996 1253 1254
100. AK Gupta RG Sibbald SR Knowles CW Lynde NH. Shear Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis J Am Acad Dermatol 36 1997 858 862
101. F Wach W Stolz R Rüdiger M. Landthaler Severe erythema annulare centrifugum–like psoriatic eruption induced by terbinafine Arch Dermatol 131 1995 960 961
102. H-L Chan RS Stern KA Arndt J Langlois SS Jick H Jick The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients Arch Dermatol 126 1990 43 47
103. AK Gupta JR Gonder NH Shear G. Dilworth The development of green vision in association with terbinafine therapy Arch Dermatol 132 1996 845 846
104. K Kruczynski MS. Balter Serum sickness-like reaction associated with oral terbinafine therapy Can J Clin Pharmacol 2 1995 129 130
105. MJ Kovacs S Alshammari L Guenther M. Bourcier Neutropenia and pancytopenia associated with oral terbinafine J Am Acad Dermatol 31 1994 806
106. HC. Health Protection Branch Canadian adverse drug reaction newsletter: terbinafine—hematological disorders Can Med Assoc J 151 1994 64 65
107. BL Strom JL Carson R Schinnar ES Snyder M. Shaw Descriptive epidemiology of agranulocytosis Arch Intern Med 152 1992 1475 1480
108. LE Böttiger B. Böttiger Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia Acta Med Scand 210 1981 475 479
109. A. Breckenridge Clinical significance of interactions with antifungal agents Br J Dermatol 126 1992 19 22
110. I Schuster NS. Ryder Allylamines: mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms J Dermatol Treat 1 1990 7 9
111. DJ Back JF Tjia SM. Abel Azoles, allylamines and drug metabolism Br J Dermatol 126 1992 14 18
112. I. Schuster The interaction of representative members from two classes of antimycotics—the azoles and the allylamines—with cytochromes P-450 in steroidogenic tissues and liver Xenobiotica 15 1985 529 546
113. A Wähllander G. Paumgartner Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers Eur J Clin Pharmacol 37 1989 279 283
114. Gupta AK, Shear NH. Attitudes of dermatologists towards prescribing for onychomycosis: a Canadian perspective. Int J Dermatol. In press.
115. SR Arikian TR Einarson G Kobelt-Nguyen FS. Schubert The Onychomycosis Study Group: a multinational pharmacoeconomic analysis of oral therapies for onychomycosis Br J Dermatol 130 1994 35 44
116. TR Einarson SR Arikian NH. Shear Cost-effective analysis for onychomycosis therapy in Canada from a government perspective Br J Dermatol 130 1994 32 34
117. TR Einarson SR Arikian NH. Shear Pharmacoeconomic analysis of oral treatments for onychomycosis: a Canadian study J Res Pharmaceutical Econ 6 1995 3 22
118. TR Einarson AK Gupta NH Shear S. Arikian Clinical and economic factors in the treatment of onychomycosis Pharmacoeconomics 9 1996 307 320
119. A Marchetti CT Piech WF McGhan AI Neuqut BT. Smith Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model Clin Ther 18 1996 757 777
120. EKA Van Doorslaer G Tormans AK Gupta K Van Rossem A Eggleston DJ Dubosi Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany Dermatology 193 1996 239 244